Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsResearch chemical TMA-2
Research chemicalPsychedelicTrimethoxyamphetamineMescaline analogue

TMA-2

Also known as 2,4,5-trimethoxyamphetamine

TMA-2 (2,4,5-trimethoxyamphetamine) is a mescaline-related trimethoxy amphetamine psychedelic, notably more potent than mescaline. Described by Shulgin, it produces a long, visual psychedelic experience and is uncommon as a research chemical.

01 Overview

TMA-2 is one of six positional isomers of trimethoxyamphetamine and the most active. It is roughly an order of magnitude more potent than mescaline, with a long duration of eight to twelve hours. It has some historical pharmacology work but no modern clinical use.

Human data are limited to old dosing accounts and anecdote. Its amphetamine backbone brings sympathomimetic and vasoconstrictive potential, and no formal toxicology exists.

02 Mechanism

5-HT2A partial agonist; the 2,4,5-trimethoxy substitution pattern with an alpha-methyl group gives higher potency and longer action than mescaline.

03 Dosing

TierDoseRouteNotes
Threshold5–10 mgOral
Common20–40 mgOralDuration 8-12 hours.

04 Effects

EffectMagnitudeEvidence
Mescaline-like visualsRich colour and geometric visuals over a long plateau.strongAnecdotal
Emotional/euphoric toneWarm, sometimes euphoric mood reported at common doses.moderateAnecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
NauseaOnset nausea typical of mescaline-type compounds.MildCommonAnecdotal
Vasoconstriction and tachycardiaRaised heart rate, blood pressure and cold extremities from the sympathomimetic amphetamine core.ModerateCommonAnecdotal

07 References

PiHKAL: A Chemical Love Story (TMA-2 entry)Shulgin & Shulgin, 1991

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.